Matrix metalloproteinase 2 and matrix metalloproteinase 9 expression in @entity1 XXXX and the effect of @entity7131 inhibitors: preliminary observations.

@entity1 @entity35958 @entity1476 @entity5 @entity957 @entity7131 @entity866 @entity1495
OBJECTIVE: The purpose of this study was to investigate gelatinase ( @entity1476 and @entity1495 ) expression in @entity957 ( @entity957 ) and to explore the mechanisms that may inhibit gelatinase activity. STUDY DESIGN: Thirty biopsy specimens of OSCCs were examined by means of immunohistochemistry. Supernatants from primary cultures of @entity1 oral mucosal keratinocyte and @entity5 -derived cells (KB and @entity35958 ) were analyzed by means of gelatin zymography. Furthermore, @entity7131 ( @entity7131 ) inhibitors (H7 and @entity866 ) were added to test how they modulate gelatinase production in @entity1 @entity5 cells. RESULTS: @entity1476 and @entity1495 expression was significantly higher in oral SCCs and was located in discrete clusters of @entity5 cells. Oral mucosal keratinocyte cultures, KB, and @entity35958 were found to secrete and produce @entity1476 and @entity1495 . However, the amounts of @entity1476 and @entity1495 were highly elevated in the 2 @entity5 cell lines in comparison with oral mucosal keratinocyte cultures (P <.05). In addition, @entity7131 inhibitors were found to decrease @entity1476 and @entity1495 activities in @entity5 cells (P <.05). CONCLUSION: Taken together, @entity1 oral SCCs produce @entity1476 and @entity1495 in vivo and in vitro, and gelatinase activity is down-regulated by @entity7131 inhibitors in vitro. @entity7131 inhibitors suppressing MMP production and/or activity may represent valuable therapeutic agents through their influence on the pathogenesis of @entity957 . These agents may prove clinically useful in combination with standard therapeutic modalities for the treatment of @entity1 with @entity5 .
